This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Concanamycin A
Accession Number
DB14062
Type
Small Molecule
Groups
Experimental
Description

Concanamycin A is an H+-ATPase (vacuolar) inhibitor.

Structure
Thumb
Synonyms
  • Concanamycin A
External IDs
Antibiotic X 4357 B / X 4357 B
Categories
UNII
Not Available
CAS number
80890-47-7
Weight
Average: 866.099
Monoisotopic: 865.518756099
Chemical Formula
C46H75NO14
InChI Key
DJZCTUVALDDONK-HQMSUKCRSA-N
InChI
InChI=1S/C46H75NO14/c1-13-16-34-28(7)37(58-38-22-33(48)43(31(10)57-38)60-45(47)53)23-46(54,61-34)30(9)41(51)29(8)42-35(55-11)18-15-17-24(3)19-26(5)39(49)32(14-2)40(50)27(6)20-25(4)21-36(56-12)44(52)59-42/h13,15-18,20-21,26-35,37-43,48-51,54H,14,19,22-23H2,1-12H3,(H2,47,53)/b16-13+,18-15+,24-17+,25-20+,36-21-/t26-,27-,28-,29+,30+,31-,32+,33-,34-,35+,37-,38+,39+,40-,41-,42-,43-,46-/m1/s1
IUPAC Name
(2R,3S,4R,6R)-6-{[(2R,4R,5S,6R)-2-[(2S,3R,4S)-4-[(2R,3S,4E,6E,9R,10S,11S,12R,13R,14E,16Z)-11-ethyl-10,12-dihydroxy-3,17-dimethoxy-7,9,13,15-tetramethyl-18-oxo-1-oxacyclooctadeca-4,6,14,16-tetraen-2-yl]-3-hydroxypentan-2-yl]-2-hydroxy-5-methyl-6-(prop-1-en-1-yl)oxan-4-yl]oxy}-4-hydroxy-2-methyloxan-3-yl carbamate
SMILES
[H][C@@]1(OC(=O)\C(OC)=C\C(\C)=C\[C@@H](C)[C@@H](O)[C@@H](CC)[C@@H](O)[C@H](C)C\C(C)=C\C=C\[C@@H]1OC)[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](O[C@H]2C[C@@H](O)[C@H](OC(N)=O)[C@@H](C)O2)[C@H](C)[C@H](O1)\C=C\C

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
AMultidrug resistance protein 1
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Concanamycin A.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Concanamycin A.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Concanamycin A.
Ascorbic acidThe serum concentration of Ascorbic acid can be increased when it is combined with Concanamycin A.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Concanamycin A.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Concanamycin A.
ChlorambucilThe serum concentration of Chlorambucil can be increased when it is combined with Concanamycin A.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Concanamycin A.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Concanamycin A.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Concanamycin A.
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
4942642
ChEBI
73167
ChEMBL
CHEMBL1241239
MSDS
Download (54.3 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0128 mg/mLALOGPS
logP4.12ALOGPS
logP5.59ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)11.68ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count12ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area225.92 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity232.65 m3·mol-1ChemAxon
Polarizability93.53 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Senior AE, al-Shawi MK, Urbatsch IL: The catalytic cycle of P-glycoprotein. FEBS Lett. 1995 Dec 27;377(3):285-9. doi: 10.1016/0014-5793(95)01345-8. [PubMed:8549739]
  2. Sharom FJ, Yu X, Chu JW, Doige CA: Characterization of the ATPase activity of P-glycoprotein from multidrug-resistant Chinese hamster ovary cells. Biochem J. 1995 Jun 1;308 ( Pt 2):381-90. [PubMed:7772017]

Drug created on June 14, 2018 13:50 / Updated on August 02, 2018 07:02